Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
News|Articles|June 25, 2026
A Death Doula on Pancreatic Cancer and the Limits of a TV Portrayal
Author(s)Cancer Network Staff
Fact checked by: Tim Cortese, Russ Conroy
INELDA-certified death doula Kim Stravers shares a detailed account of supporting a patient with pancreatic cancer and Lynch syndrome.
Advertisement
Advertisement
Kim Stravers is a certified end-of-life doula and educator with the International End of Life Doula Association (INELDA), with additional proficiency through the National End-of-Life Doula Alliance (NEDA). She is based in the Phoenix, Arizona area, volunteers with a local hospice organization, and provides private doula services to patients navigating serious illness and their circles of care.
Related to this article
“If it is successful, you should be able to access this combination wherever you are,” said Natalie S. Callander, MD, of the UW Carbone Cancer Center.
"As we combine more treatments…they have overlapping toxicities, and they may have the ability to synergize in a negative way," said Dwight H. Owen, MBBCh, MS.
“What we are trying to do more often is to ablate as much as we can,” said Shankar Siva, MBBS, PhD, FRANZCR, on pairing SABR with systemic therapy in RCC.
Translating laboratory discoveries into clinical benefit increasingly depends on combining genomic profiling with newer tools, including patient-derived functional models and artificial intelligence AI.
“The more representation, the more people we have participating in clinical trials, the more applicable the data,” said Patricia A. Robinson, MD.
Subgroup analyses of the phase 3 RASolute 302 trial showed overall survival favored daraxonrasib over chemotherapy in metastatic pancreatic cancer.
The FDA based its approval of pembrolizumab on findings from the phase 2 KEYNOTE-158 trial.
Advertisement
Advertisement